

URBANET NAGOYA NEXTA Bldg.
1-1-1 Higashisakura, Higashi-ku, Nagoya

September 26, 2022

NGK SPARK PLUG CO., LTD.

**Notice of investment from NGK SPARK PLUG CO., LTD. CVC Fund
to healthcare startup NOTA Laboratories (Michigan, USA)
~Convenient, low-cost on-demand generation of nitric oxide (NO) expands the
potential to treat a variety of respiratory and inflammatory diseases using this
powerful molecule~**

NGK SPARK PLUG CO., LTD. (President: Takeshi Kawai, Headquarters: Higashi-ku, Nagoya) have invested in the startup company NOTA Laboratories (Headquarters: Michigan, US, hereinafter NOTA Labs), which company develops nitric oxide (NO) inhalation therapy products, through a CVC fund (*1) jointly operated with Pegasus Tech Ventures.

NOTA Labs has been developing a unique nitric oxide delivery system to treat acute and chronic respiratory and inflammatory diseases. Using patented technology, the company's product is capable of producing nitric oxide on demand and is expected soon to be commercialized as an ideal solution for hospital environments.

In the "2030 Long-Term Management Plan NITTOKU BX", we have set out the "transformation of our business portfolio" to increase the ratio of non-internal combustion engine business, and as one of the measures to realize it, we are promoting the creation of new businesses in the areas of "Smart Health", "Decentralized Utilities" and "Smart Mobility". As a part of that effort in "Smart Health", a Joint Development Agreement (JDA) with NOTA Labs has been signed to develop healthcare products for a wide variety of respiratory diseases within the hospital and home care settings, combining NOTA Labs's technology with our oxygen concentrator technology.

We will continue to promote the creation of new businesses by investing in and forming alliances with companies with cutting-edge technologies around the world, and will continue our best efforts to create new value.

(*1) [Notice of establishment of CVC fund \(March 29, 2021\)](#)

URBANET NAGOYA NEXTA Bldg.
 1-1-1 Higashisakura, Higashi-ku, Nagoya

■NOTA Labs has two platform technologies

The NOGEN™ system produces on-demand NO using an electrochemical reaction and can operate for months on end in the hospital setting without changing consumables. It is initially targeted toward persistent pulmonary hypertension of the newborn (PPHN) and is expected to see significant usage in open-heart surgery and a wide range of other respiratory conditions, including bronchiolitis.

NOTA's second platform technology is named LANOR. It employs light activated chemistry on a filmstrip to generate NO and is ideally suited for future in-home and first responder applications of NO, such as chronic obstructive pulmonary disease (COPD).



Images of the product (NOGEN)

■ Overview of NOTA Laboratories

Company Official Name	NOTA Laboratories
Location	600 South Wagner Road Suite 6 Ann Arbor, MI 48103, United States
Year of establishment	2014
Management	CEO : Malcolm Kahn
Business description	Developing healthcare products for respiratory diseases, using nitric oxide (NO)
Website	https://www.notalabs.com/